If you have been reading about GLP-1 receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-08. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Business Secretary Kemi Badenoch tells the House of Commons that allegations by Henry Staunton, the former chair of the Post Office, that he was told to delay compensation payments for sub-postmasters are "completely false". The UK government announces plans for new measures on holiday homes in England to stop local people being priced out of being able to live in their community. Ofcom launches an impartiality investigation into GB News's Q&A session with prime minister Rishi Sunak. The UK government announces that a scheme allowing Ukrainian nationals to join relatives in the UK has closed to new applicants. Birmingham City Council announces plans to raise council tax by 21% over the next two years as part of £300m in budget cuts. 20 February – BBC News reports that the Cameron government were aware that the Post Office had ended a 2016 investigation that could have helped several sub-postmasters wrongly convicted as a result of the Horizon IT scandal. Labour calls for an immediate humanitarian ceasefire in Gaza, the first time it has called for a ceasefire since the Israel–Hamas conflict began. In a statement on the Israel–Hamas conflict, the Prince of Wales calls for an "end to the fighting as soon as possible". David Neal is dismissed from the post of Independent Chief Inspector of Borders and Immigration after he was quoted in articles criticising the immigration system in both The Times and the Daily Mail.
In September 2016, Inhixa and Thorinane were approved for use in the European Union. Thorinane was withdrawn from the market in October 2019. In March 2017, Enoxaparin BECAT, Laboratorios ROVI (Spain) obtained marketing authorization in twenty six countries in Europe. The product is now available in Europe. In October 2020, Noromby and Noromby HP, were approved for medical use in Canada. In November 2020, Inclunox and Inclunox HP were approved for medical use in Canada. In December 2020, Redesca and Redesca HP were approved for medical use in Canada.
The move resulted in a backlash from the gaming community, and Firewatch was "review-bombed" on Steam. Ars Technica noted that the company previously stated on their website that they gave open permission to stream and monetize videos made while playing the game. On April 21, 2018, Campo Santo announced that they had been acquired by Valve and would subsequently move to Valve's Bellevue, Washington headquarters and continuing In the Valley of Gods as a Valve game. According to Vanaman and Rodkin, after the success of Firewatch, they started internal discussions of where they wanted to take their company. These discussions continued informally with third parties, including Valve's Robin Walker, Erik Johnson and Scott Lynch. These Valve employees suggested that Campo Santo could retain its own direction while being wholly within Valve, yet still draw from Valve's knowledge and expertise. Vanaman and Rodkin discussed this more formally with Valve, ultimately leading to the acquisition. Development on In The Valley of Gods was put on hold in July 2019, partially due to head writer Sean Vanaman moving to the writing team for Half-Life: Alyx, which had not been announced to the public at the time. In November 2019, it was noted by journalists that Claire Hummel, Jane Ng, and Rodkin had removed In the Valley of Gods from their Twitter profile descriptions. The game also disappeared from Campo Santo's website and the original announcement trailer was made private on YouTube, though the website and its Steam profile page were still available.
A meta-analysis released subsequently showed that pioglitazone reduced the risk of ischemic cardiac events rather than increased the risk, but increased CHF. A 2020 Cochrane systematic review assessed occurrence of adverse effects with use of pioglitazone, but was not able to reach any conclusions due to insufficient data on included studies.
Sources: en.wikipedia.org
== Impact == Since its initial publication, the monograph has come to be seen as a highly influential work in the field of mathematical biology. It serves as the essential text for most high level mathematical biology courses around the world, and is credited with transforming the field from a niche subject into a standard research area of applied mathematics.
My fellow Americans, I'm pleased to tell you that today I signed legislation that will allow student religious groups to begin enjoying a right they've too long been denied—the freedom to meet in public high schools during non-school hours, just as other student groups are allowed to do. Following his trip to Los Angeles in 1959 and being refused entry into Disneyland, on security grounds, a dejected Soviet Premier Nikita Khrushchev joked, "... just now I was told that I could not go to Disneyland, I asked 'Why not?' What is it, do you have rocket launching pads there?" The only person more disappointed than Khrushchev was Walt Disney himself, who claimed he had been looking forward to showing off his 'submarine fleet', which was actually the Submarine Voyage ride.
== Ecology and status == Because pine nuts are an important food source for many animals, overharvesting of pine nuts threatens local ecosystems, an effect occurring during the early 21st century with increased culinary uses for pine nuts. In the United States, millions of hectares of productive pinyon pine woods have been destroyed due to conversion of lands, and in China and Russia, destructive harvesting techniques (such as breaking off whole branches to harvest the cones) and removal of trees for timber have led to losses in production capacity.
Type 1 diabetes Type 2 diabetes Hybrid forms of diabetes(including slowly evolving, immune-mediated diabetes of adults and ketosis-prone type 2 diabetes) Hyperglycemia first detected during pregnancy Other specific types Unclassified diabetes Diabetes is a more variable disease than once thought, and individuals may have a combination of forms.
== Fungus-derived == Edible mushrooms Mycoprotein – a form of single-cell protein, also known as fungal protein, it is able to provide greater satiety than traditional protein sources such as chicken, while also being rich in protein and low in caloric content Fistulina hepatica – a common mushroom known as beefsteak fungus Fusarium venenatum – a microfungus of the genus Fusarium that has a high protein content Hericium erinaceus – also known as lion's mane mushroom and has been explored as a steak alternative Laetiporus – a mushroom which is also named chicken of the woods Lyophyllum decastes – a mushroom known as fried chicken mushroom Neurospora crassa – a type of red bread mold of the phylum Ascomycota Pleurotus ostreatus – better known as the oyster mushroom, famous in the vegan community as one of the best substitutes for fried chicken
Sources: en.wikipedia.org
== Operation and features == Most freeze alarms combine a temperature sensor with either a local indicator or a remote communication module. A typical residential set-point is between 10–13 °C (50–55 °F), providing a margin above the freezing point of water. Early products such as the Honeywell “Winter Watchman” used a simple thermostat that closed a circuit to flash a lamp when indoor temperature dropped, alerting neighbours passing by. Contemporary units use solid-state sensors and microcontrollers, allowing adjustable thresholds, continuous logging, and multi-condition monitoring (e.g. power loss, humidity, water leaks, or smoke-alarm sound detection).
The GHRL gene produces mRNA which has four exons. Five products arise: the first is the 117-amino acid preproghrelin. It is homologous to promotilin; both are members of the motilin family. It is cleaved to produce proghrelin which is cleaved to produce an unacylated 28-amino acid ghrelin and an acylated C-ghrelin. Obestatin is presumed to be cleaved from C-ghrelin. Ghrelin only becomes active when caprylic (octanoic) acid is linked posttranslationally to serine at the 3-position by the enzyme ghrelin O-acyltransferase (GOAT) to form a proteolipid. It is located on the cell membrane of ghrelin cells in the stomach and pancreas. The non-octanoylated form is desacyl ghrelin. It does not activate the GHS-R receptor but does have other effects: cardiac, anti-ghrelin, appetite stimulation, and inhibition of hepatic glucose output. Side-chains other than octanoyl have also been observed: these can also trigger the ghrelin receptor. In particular, decanoyl ghrelin has been found to constitute a significant portion of circulating ghrelin in mice, but as of 2011 its presence in humans has not been established.
The topical formulations have not been associated with liver damage, adrenal problems, or drug interactions. These formulations include creams, shampoos, foams, and gels applied to the skin, unlike the ketoconazole tablets, which are taken by mouth.
=== Treatment === To treat the food, it is exposed to a radioactive source for a set period of time to achieve a desired dose. Radiation may be emitted by a radioactive substance, or by X-ray and electron beam accelerators. Special precautions are taken to ensure the food stuffs never come in contact with the radioactive substances and that the personnel and the environment are protected from radiation exposure. Irradiation treatments are typically classified by dose (high, medium, and low), but are sometimes classified by the effects of the treatment (radappertisation, radicidation and radurisation). Food irradiation is sometimes referred to as "cold pasteurisation" or "electronic pasteurisation" because ionising the food does not heat it to high temperatures during the process, and the effect is similar to pasteurisation. The term "cold pasteurisation" is controversial because the term may be used to disguise the fact that the food has been irradiated, and pasteurisation and irradiation are fundamentally different processes.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.